Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
BeiGene, Ltd.

BeiGene, Ltd. (BGNE) Stock Overview

Explore BeiGene, Ltd.’s financial performance, market position, analyst ratings, and future outlook.

BGNE●NASDAQ
HealthcareBiotechnology
$184.71
$0.90(0.49%)
U.S. Market is Open · 15:28

BeiGene, Ltd. (BGNE)

Meyka AI Score

Z

Key Financials

Market Cap20.2B
P/E Ratio3.06
EPS (TTM)$-8.19
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$137.76

BGNE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of BeiGene, Ltd. (NASDAQ: BGNE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, BeiGene, Ltd.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BGNE on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $137.76 for the NASDAQ listing.

Key metrics behind BeiGene, Ltd.'s NASDAQ-traded stock include a P/E ratio of 3.06 and a market capitalization of 20.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BGNE on the NASDAQ.

Price Performance (NASDAQ: BGNE)

1-Day Change
-18.53%
5-Day Change
-15.11%
1-Month Change
0.49%
3-Month Change
-10.33%
6-Month Change
17.66%
Year-to-Date (YTD) Change
0.39%
1-Year Change
19.14%
3-Year Change
-23.86%
5-Year Change
20.34%
All-Time (Max) Change
552.22%

Contact Information

https://beonemedicines.com
781-801-1800
55 Cambridge Parkway, Cambridge, MA, 02142

Company Facts

106,000 Employees
IPO DateFeb 3, 2016
CountryUS

Frequently Asked Questions